by Plus Therapeutics | Feb 25, 2026 | GBM
Plus Therapeutics announced that the American Medical Association (AMA) CPT® Editorial Panel has approved a new Category III CPT code to track the utilization of convection‑enhanced delivery (CED) when used in the administration of REYOBIQ™ for patients with recurrent...
by Plus Therapeutics | Feb 6, 2026 | GBM
ReSPECT Clinical Trial’s Dr. Brenner recently participated in another Stand Up To Cancer® (SU2C) Innovation Summit, focused on advancing novel approaches for the detection and treatment of gliomas, a complex and aggressive form of brain cancer. The summit...
by Plus Therapeutics | Nov 26, 2025 | GBM
Innovations in brain cancer treatment continue to advance, fueled by the dedication of leading clinicians and researchers across the globe. In the latest episode of the Game On Glio podcast, Toral Patel, MD (UT Southwestern Medical Center) and Andrew Brenner, MD, PhD...
by Plus Therapeutics | Nov 14, 2025 | GBM
Plus Therapeutics is proud to share that the ReSPECT-GBM clinical trial is now a featured study on the American Brain Tumor Association (ABTA) website. This recognition highlights the growing visibility and clinical importance of our work to develop new therapeutic...
by Plus Therapeutics | Sep 17, 2025 | GBM, PBC
Each September, Childhood Cancer Awareness Month (#CCAM) serves as a powerful reminder to honor children and families affected by pediatric cancer and to raise awareness for the urgent need for new treatment options. At Plus Therapeutics (Nasdaq: PSTV), we are deeply...
by Plus Therapeutics | Aug 7, 2025 | GBM
Glioblastoma (GBM) is one of the most aggressive and challenging forms of brain cancer, with limited treatment options available today. At Plus Therapeutics (NASDAQ: PSTV), we are committed to developing new therapies that can bring hope to patients and their...
Recent Comments